Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Broad-Based Genomic Sequencing and Survival Outcomes in Advanced Non-Small Cell Lung Cancer: 2016-2022.

Created on 13 Nov 2026

Authors

Patricia Mae G Santos, Lillian A Boe, Kawther Al Ksir, Ticiana Leal, Daniel R Gomez, Ravi B Parikh

Published in

Journal of the National Comprehensive Cancer Network : JNCCN. Volume 24. Issue 11.

Abstract

Nearly half of patients with advanced non-small cell lung cancer (aNSCLC) have actionable mutations that can be detected through broad-based genomic sequencing (BGS) or focused biomarker testing (FBT). Although national guidelines advocate for early BGS, its impact on survival in the era of targeted therapy remains unclear. This study evaluates whether BGS is associated with improved progression-free survival (PFS) and overall survival (OS) compared with FBT.
This retrospective cohort study used electronic health record data from the Flatiron Health Research Database (2016-2022), which includes data from approximately 280 US academic and community oncology clinics. Adults (age ≥18 years) with stage IIIB-IV NSCLC who received at least one line of systemic therapy were included. Patients were categorized based on receipt of BGS or FBT <3 months before initiation of first- and second-line systemic therapy. Propensity score matching (1:1) was used to adjust for baseline demographic, clinical, and practice covariates. Primary and secondary outcomes were median PFS and median OS, respectively. Adjusted Cox proportional hazards models estimated hazard ratios (HRs), with sensitivity analyses accounting for biomarker status, restricted mean survival times, and an instrumental variable approach.
Among 35,060 eligible patients (BGS, n=14,192; FBT, n=20,868), 20,016 were included in the matched first-line analyses. BGS was associated with improved median PFS (6.4 vs 6.0 months; adjusted HR, 0.96 [95% CI, 0.92-1.00]; P=.046) and median OS (16 vs 14 months; adjusted HR, 0.91 [95% CI, 0.86-0.95]; P<.001). Patients who underwent BGS had higher biomarker positivity (60% vs 22%) and targeted therapy use (19% vs 16%). Sensitivity analyses supported these findings. BGS was not associated with improved outcomes in the matched second-line cohort.
BGS was associated with improved PFS and OS in the first-line setting but not the second-line setting, supporting its routine use and insurance coverage in clinical practice.

PMID:
43019765
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement